This project seeks to document that Janus kinase 3 (Jak3), an enzyme exclusively associated with the common y chain (yc) receptor used by a limited number of T-cell growth factors (interleukin [IL] -2, -4, -7, -9-13, and -15) to trigger T, B, monocyte and natural killer cells, represents a more specific target for immunosuppression than the ubiquitously expressed proteins, calcineurin (CaN) or mammalian target of rapamycin (mTOR). We plan to demonstrate that Jak3 blockade specifically interrupts membrane-associated, as well as downstream, enzymatic and transcriptional 1-cell activation events mediated by Cytokine Signal 3, but not by Antigen Signal 1 or by Co-stimulatory Signal 2, using immunoprecipitation, Western blot, cold kinase, electrophoretic mobility shift/supershift, quantitative PCR, fluorescence activated scanning and ribonuclease protection assays. Furthermore, we postulate that Jak3 blockade not only impairs cell cycle progression but also promotes T-cell apoptosis, thereby exerting immunosuppressive effects to prolong the survival of heterotopic cardiac and life-sustaining renal transplants in rats. To confirm that the in vivo effects correlate with in vitro molecular profiles, the biochemical assays are performed on lymphocytes infiltrating irradiated spleen allografts transplanted into recipients treated with Jak3 antagonists. Further, we seek to show that the immunosuppressive effects of Jak3 inhibition are synergistic with agents that blockade either Signal l(CaN) or Signal 2 (CD28), but not Signal 3 (mTOR) using the median effect model to correlate outcomes with drug doses/concentrations. Due to the limited tissue expression profile of Jak3, we doubt that blockade of its activity causes or potentiates the nephrotoxic, myelosuppressive and/or lipotoxic effects of CaN or mTOR inhibitors. Although the proposed experiments utilize a selective dodecyl alicyclic ketone inhibitor of Jak3 but not Jak2, alternative approaches (aside from identification of other drugs) include the use of Jak3 antisense oligonucleotides and/or adoptive transfer of T-cells transfected with a dominant-negative, inactive Jak3 variant to reconstitute the immune system of irradiated hosts.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK038016-16
Application #
6523997
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Eggers, Paul Wayne
Project Start
1986-12-01
Project End
2005-08-31
Budget Start
2002-09-01
Budget End
2003-08-31
Support Year
16
Fiscal Year
2002
Total Cost
$298,000
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Surgery
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77225
Benavides, Carlos A; Pollard, Vida B; Mauiyyedi, Shamila et al. (2007) BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 84:83-8
Yakupoglu, Y K; Buell, J F; Woodle, S et al. (2006) Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 38:358-61
Lisik, W; Kahan, B D (2006) Individualization of immunosuppressive therapy. II. Sirolimus as a less nephrotoxic alternative to calcineurin inhibitors. Transplant Proc 38:69-73
Csapo, Z; Benavides-Viveros, C; Podder, H et al. (2005) Campath-1H as rescue therapy for the treatment of acute rejection in kidney transplant patients. Transplant Proc 37:2032-6
Kahan, Barry D; Yakupoglu, Yarkin K; Schoenberg, Linda et al. (2005) Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 80:749-58
Chen, Wenhau; Langer, Robert M; Janczewska, Slawa et al. (2005) Methoxyethyl-modified intercellular adhesion molecule-1 antisense phosphorothiateoligonucleotides inhibit allograft rejection, ischemic-reperfusion injury, and cyclosporine-induced nephrotoxicity. Transplantation 79:401-8
Chueh, Shih-Chieh J; Kahan, Barry D (2005) Clinical application of sirolimus in renal transplantation: an update. Transpl Int 18:261-77
Podder, H; Kahan, B D (2005) Individualization of immunosuppressive therapy: I. Sirolimus improves outcomes in african-american renal transplant recipients. Transplant Proc 37:3723-6
Bai, Shuang; Stepkowski, Stanislaw M; Kahan, Barry D et al. (2004) Metabolic interaction between cyclosporine and sirolimus. Transplantation 77:1507-12
Kahan, Barry D (2004) Sirolimus-based immunosuppression: present state of the art. J Nephrol 17 Suppl 8:S32-9

Showing the most recent 10 out of 155 publications